Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10)

Oncology Reports

Volumn 29, Issue 6, 2013, Pages 2479-2485

  Deng, Wen ^a   Dai, Chun Ling ^a,b   Chen, Jun Jiang ^a,c   Kathawala, Rishil J ^a   Sun, Yue Li ^a,b   Chen, Hai Fan ^d   Fu, Li Wu ^b   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^d Primary Care Medicine Associates PC   (United States)

Author keywords

ATP binding cassette transporter; FMS like tyrosine kinase 3; Multidrug resistance; Multidrug resistance protein 7 ABCC10; Tandutinib

Indexed keywords

CISPLATIN; LAPATINIB; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 7; PACLITAXEL; PACLITAXEL H 3; RADIOPHARMACEUTICAL AGENT; TANDUTINIB; TRITIUM; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG INHIBITION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; HUMAN CELL; IC 50; INTRACELLULAR TRANSPORT; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; STRUCTURE ANALYSIS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PACLITAXEL; PIPERAZINES; QUINAZOLINES; VINCRISTINE;

EID: 84876239961     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2362     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008. (Pubitemid 351521864)
2. Wu CP, Calcagno AM and Ambudkar SV: Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 1: 93-105, 2008.
3. Bradbury PA and Middleton MR: DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 15: 421-426, 2004. (Pubitemid 38736939)
4. Deeley RG, Westlake C and Cole SPC: Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86: 849-899, 2006. (Pubitemid 44033384)
5. Borges-Walmsley MI, McKeegan KS and Walmsley AR: Structure and function of efflux pumps that confer resistance to drugs. Biochem J 376: 313-338, 2003. (Pubitemid 38010517)
6. Sodani K, Patel A, Kathawala RJ and Chen ZS: Multidrug resistance associated proteins in multidrug resistance. Chin J Cancer 31: 58-72, 2012.
7. Chen ZS and Tiwari AK: Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J 278: 3226-3245, 2011.
8. Naramoto H, Uematsu T, Uchihashi T, et al: Multidrug resistance- associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines. Int J Oncol 30: 393-401, 2007.
9. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG and Kruh GD: Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 64: 4927-4930, 2004. (Pubitemid 38924539)
10. Hopper-Borge E, Xu X, Shen T, et al: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epithilone B. Cancer Res 69: 178-184, 2009.
11. Zhou Y, Hopper-Borge E, Shen T, et al: Cepharanthine is a potent reversal agent for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol 77: 993-1001, 2009.
12. Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799, 2003. (Pubitemid 46606324)
13. Hirota S, Isozaki K, Moriama Y, et al: Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 279: 577-580, 1998. (Pubitemid 28067289)
14. Shah NP, Nicoll JM, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125, 2002. (Pubitemid 41039112)
15. + cells and is inhibited by imatinib mesylate. Blood 108: 1370-1373, 2006.
16. Schittenhelm MM, Shiraga S, Schroeder A, et al: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66: 473-481, 2006. (Pubitemid 43166056)
17. Hiwase DK, Saunders V, Hewett D, et al: Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 14: 3881-3888, 2008.
18. Gora-Tybor J and Robak T: Targeted drugs in chronic myeloid leukemia. Curr Med Chem 15: 3036-3051, 2008.
19. Zhang H, Peng C, Hu Y, et al: The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells. Nat Genet 44: 861-871, 2012.
20. Shi Z, Peng XX, Kim IW, et al: Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67: 11012-11020, 2007. (Pubitemid 350145931)
21. Dai C, Tiwari AK, Wu CP, et al: Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68: 7905-7914, 2008.
22. Tiwari AK, Sodani K, Wang SR, et al: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXP transporters. Biochem Pharmacol 78: 153-161, 2009.
23. Shen T, Kuang YH, Ouyang J, et al: Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7(ABCC10). PLoS One 4: e7520, 2009.
24. Kuang YH, Shen T, Sodani K, et al: Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol 79: 154-161, 2009.
25. DeAngelo DJ, Stone RM, Heaney ML, et al: Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 108: 3674-3681, 2006. (Pubitemid 44864544)
26. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E and Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol 63: 351-358, 2003. (Pubitemid 36158370)
27. Bliss CI: The calculation of the dose-mortality curve. Ann Appl Biol 22: 134-167, 1935.
28. Tiwari AK, Sodani k, Dai CL, et al: Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett 328: 307-317, 2012.
29. Yang JJ, Milton MN, Yu S, et al: P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metab Lett 4: 201-212, 2010.
30. Kantarjian H, Giles F, Wunderle L, et al: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New Eng J Med 354: 2542-2551, 2006. (Pubitemid 43882350)
31. Tanaka C, Yin OQ, Sethuraman V, et al: Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 872: 197-203, 2010.